To all: I have sold my ISIP stocks after the recent run up. However, I think the company is solid and it's future is bright. The reason for selling is the belief that when stocks in general tanks, the big, overvalued guys will bring everyone else with them, however undervalued. There also seems to be a great deal of negative sentiment against small biotechs in general and Isis in particular, probably desseminated by shorts. I attended a presentation by an Isis scientist at the recent American Academy of Allergy and Immunology meeting at Orlando. Things seem to be progressing well and they certainly have several promising candidates including compounds targeting ICAM1, VLA4, H-ras. THe beauty is, all these compunds may have several disease targets since they take aim at fundamental processes involved in inflammation or carcinogenesis. The ICAM1 product, in particular, should have important data coming out within the next year or so. If the results are good, I won't worry too much about the 2 year cash reserve. I also don't have any doubt that antisense works; you can demonstrate the presence of antisense molecules in target organs by in-situ hybridization, and you can also demonstrate downregulation of mRNA by RT-PCR or RNAse protection. What more do you need.
If the stock goes back to 7, I will be a big buyer.
Adrian Wu |
